arrow
M

Masahiro Tajika

aichi cancer center
H指数:46
被引数:7,574

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5-Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single-Institute Propensity Score Analysis

新辅助多西他赛、顺铂和5-氟尿嘧啶疗法对伴有多发性淋巴结转移的食管鳞状细胞癌患者的潜在生存获益:一项单中心倾向性评分分析

2026-04-190
OAAI
Risk Factors for Metastasis and Prognosis in Non-Curative Resection After Endoscopic Submucosal Dissection for Undifferentiated-Type Early Gastric Cancer in a Nationwide Cohort in Japan

非治愈性切除后未分化型早期胃癌转移和预后的风险因素:一项基于日本全国队列的研究

2026-04-090
PRE
Long-term prognosis of mixed histological-type gastric cancers cured by endoscopic resection: a multicenter prospective cohort study

混合组织学类型胃癌经内镜切除后的长期预后:一项多中心前瞻性队列研究

2025-08-030
PRE
Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study

奥沙利铂和5-氟尿嘧啶联合多西他赛新辅助治疗食管癌期间发热性中性粒细胞减少症的最佳一级预防:一项回顾性队列研究

2025-04-240
OAAI
Conversion from Radical Esophagectomy to Definitive Chemoradiotherapy After Neoadjuvant Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: Treatment Options Based on Chemotherapy Response

进展期食管鳞状细胞癌新辅助化疗后从根治性食管切除术转为确定性放化疗: 基于化疗反应的治疗选择

2025-02-140
PRE
PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer

PRABITAS研究:一项关于三周一次与常规用法三氟尿idine/替吡拉塞联合贝伐珠单抗治疗难治性转移性结直肠癌的实用型、随机化、III期临床试验

2024-09-010
PRE